» Articles » PMID: 12125983

Differential Expression of SOX4 and SOX11 in Medulloblastoma

Overview
Journal J Neurooncol
Publisher Springer
Date 2002 Jul 20
PMID 12125983
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Primitive neuroectodermal tumors (PNETs) are composed of immature neuronal precursor cells and sometimes more mature neuronal cell types. Medulloblastomas, occuring in the cerebellum, represent the most common PNET and are broadly classified into two subgroups: classical and desmoplastic. Desmoplastic medulloblastomas exhibit a slightly better prognosis than classical medulloblastomas. However, there are currently no good molecular markers available to distinguish clinical outcome and similar treatment is used for most patients with associated complications. It has been shown that neoplastic cells in these tumors recapitulate stages in maturation of normal human neuroblasts; therefore, embryological studies of the earliest events in the development of the cerebellum may provide useful information about the molecular behavior of the tumor. Transcription factors such as Sox proteins involved in neural development may also play a role in the etiology of brain tumors. Sox4 in particular has been implicated in the biology of several other types of cancer. We have studied the expression of Sox4, and the closely related Sox11 gene, in medulloblastomas. Sox4 and Sox11 were strongly expressed in most classical medulloblastomas but only weakly in desmoplastic medulloblastomas. The expression profile of these two genes in developing cerebellum was also analyzed. Our results suggest that strong Sox4 and Sox11 expression in classical medulloblastomas reflects their maturation-dependent expression during normal cerebellum development, and that they may therefore provide markers to divide tumors into clinically relevant subgroups.

Citing Articles

Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.

Zhong J, Xiang D, Ma X Biomed Res Int. 2022; 2022:2309339.

PMID: 35845958 PMC: 9283042. DOI: 10.1155/2022/2309339.


The Role of Neurodevelopmental Pathways in Brain Tumors.

Curry R, Glasgow S Front Cell Dev Biol. 2021; 9:659055.

PMID: 34012965 PMC: 8127784. DOI: 10.3389/fcell.2021.659055.


SOX4: The unappreciated oncogene.

Moreno C Semin Cancer Biol. 2019; 67(Pt 1):57-64.

PMID: 31445218 PMC: 7043201. DOI: 10.1016/j.semcancer.2019.08.027.


SOX11: friend or foe in tumor prevention and carcinogenesis?.

Yang Z, Jiang S, Lu C, Ji T, Yang W, Li T Ther Adv Med Oncol. 2019; 11:1758835919853449.

PMID: 31210798 PMC: 6547177. DOI: 10.1177/1758835919853449.


Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance.

Mehta G, Khanna P, Gatza M J Mammary Gland Biol Neoplasia. 2019; 24(3):213-230.

PMID: 31069617 PMC: 6790170. DOI: 10.1007/s10911-019-09430-6.


References
1.
Pusch C, Hustert E, Pfeifer D, Sudbeck P, Kist R, Roe B . The SOX10/Sox10 gene from human and mouse: sequence, expression, and transactivation by the encoded HMG domain transcription factor. Hum Genet. 1998; 103(2):115-23. DOI: 10.1007/s004390050793. View

2.
Xia Y, Papalopulu N, Vogt P, Li J . The oncogenic potential of the high mobility group box protein Sox3. Cancer Res. 2000; 60(22):6303-6. View

3.
Katsetos C, Burger P . Medulloblastoma. Semin Diagn Pathol. 1994; 11(2):85-97. View

4.
Iijima M, Nakazato Y . Pale islands in medulloblastoma consist of differentiated cells with low growth potential. Pathol Int. 1997; 47(1):25-30. DOI: 10.1111/j.1440-1827.1997.tb04431.x. View

5.
Bodey B, Bodey Jr B, Siegel S, Kaiser H . Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in childhood medulloblastomas/primitive neuroectodermal tumors. Anticancer Res. 2000; 20(3A):1769-80. View